Last reviewed 2026-04-20 · How we verify

4L Polyethylene Glycol

4L Polyethylene Glycol, marketed by Changhai Hospital, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy (NA)
• Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC) (PHASE4)
• Efficacy, Safety and Tolerability of Magnesium Sulfate With Low-volume Polyethylene Glycol for Colonoscopy Cleansing (NA)
• Mechanical Bowel Preparation Versus no Bowel Preparation for Esophageal Cancer Surgery (NA)
• Optimization of Intestinal Preparation in Older Patients (NA)
• Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic Constipation (NA)
• Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG (PHASE4)
• Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• 4L Polyethylene Glycol CI brief — competitive landscape report
• 4L Polyethylene Glycol updates RSS · CI watch RSS
• Changhai Hospital portfolio CI